Israel · Delayed Price · Currency is ILS · Price in ILA Together Pharma Statistics
Total Valuation
Together Pharma has a market cap or net worth of ILS 48.38 million. The enterprise value is 98.02 million.
| Market Cap | 48.38M |
| Enterprise Value | 98.02M |
Important Dates
The next estimated earnings date is Friday, May 29, 2026.
| Earnings Date | May 29, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Together Pharma has 17.35 million shares outstanding. The number of shares has increased by 27.26% in one year.
| Current Share Class | 17.35M |
| Shares Outstanding | 17.35M |
| Shares Change (YoY) | +27.26% |
| Shares Change (QoQ) | +21.96% |
| Owned by Insiders (%) | 75.15% |
| Owned by Institutions (%) | 0.00% |
| Float | 4.31M |
Valuation Ratios
The trailing PE ratio is 23.24.
| PE Ratio | 23.24 |
| Forward PE | n/a |
| PS Ratio | 0.44 |
| PB Ratio | 0.96 |
| P/TBV Ratio | 2.05 |
| P/FCF Ratio | 9.37 |
| P/OCF Ratio | 7.35 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 4.30, with an EV/FCF ratio of 18.97.
| EV / Earnings | 51.26 |
| EV / Sales | 0.89 |
| EV / EBITDA | 4.30 |
| EV / EBIT | 6.44 |
| EV / FCF | 18.97 |
Financial Position
The company has a current ratio of 1.32, with a Debt / Equity ratio of 1.19.
| Current Ratio | 1.32 |
| Quick Ratio | 0.41 |
| Debt / Equity | 1.19 |
| Debt / EBITDA | 2.62 |
| Debt / FCF | 11.57 |
| Interest Coverage | 2.26 |
Financial Efficiency
Return on equity (ROE) is 4.34% and return on invested capital (ROIC) is 6.14%.
| Return on Equity (ROE) | 4.34% |
| Return on Assets (ROA) | 6.32% |
| Return on Invested Capital (ROIC) | 6.14% |
| Return on Capital Employed (ROCE) | 18.42% |
| Weighted Average Cost of Capital (WACC) | 5.16% |
| Revenue Per Employee | 522,038 |
| Profits Per Employee | 9,105 |
| Employee Count | 210 |
| Asset Turnover | 0.73 |
| Inventory Turnover | 1.31 |
Taxes
In the past 12 months, Together Pharma has paid 2.96 million in taxes.
| Income Tax | 2.96M |
| Effective Tax Rate | 60.64% |
Stock Price Statistics
The stock price has decreased by -34.07% in the last 52 weeks. The beta is 0.33, so Together Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.33 |
| 52-Week Price Change | -34.07% |
| 50-Day Moving Average | 306.11 |
| 200-Day Moving Average | 349.34 |
| Relative Strength Index (RSI) | 44.96 |
| Average Volume (20 Days) | 9,952 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Together Pharma had revenue of ILS 109.63 million and earned 1.91 million in profits. Earnings per share was 0.12.
| Revenue | 109.63M |
| Gross Profit | 31.49M |
| Operating Income | 15.23M |
| Pretax Income | 4.87M |
| Net Income | 1.91M |
| EBITDA | 21.28M |
| EBIT | 15.23M |
| Earnings Per Share (EPS) | 0.12 |
Balance Sheet
The company has 12.22 million in cash and 59.75 million in debt, with a net cash position of -47.53 million or -2.74 per share.
| Cash & Cash Equivalents | 12.22M |
| Total Debt | 59.75M |
| Net Cash | -47.53M |
| Net Cash Per Share | -2.74 |
| Equity (Book Value) | 50.14M |
| Book Value Per Share | 2.77 |
| Working Capital | 22.71M |
Cash Flow
In the last 12 months, operating cash flow was 6.58 million and capital expenditures -1.41 million, giving a free cash flow of 5.17 million.
| Operating Cash Flow | 6.58M |
| Capital Expenditures | -1.41M |
| Depreciation & Amortization | 6.05M |
| Net Borrowing | 4.08M |
| Free Cash Flow | 5.17M |
| FCF Per Share | 0.30 |
Margins
Gross margin is 28.72%, with operating and profit margins of 13.89% and 1.74%.
| Gross Margin | 28.72% |
| Operating Margin | 13.89% |
| Pretax Margin | 4.45% |
| Profit Margin | 1.74% |
| EBITDA Margin | 19.41% |
| EBIT Margin | 13.89% |
| FCF Margin | 4.71% |
Dividends & Yields
Together Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -27.26% |
| Shareholder Yield | -27.26% |
| Earnings Yield | 3.95% |
| FCF Yield | 10.68% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on August 13, 2023. It was a reverse split with a ratio of 0.1.
| Last Split Date | Aug 13, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
Together Pharma has an Altman Z-Score of -0.35 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.35 |
| Piotroski F-Score | 7 |